Loading...
Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)
22-Oct-2008
- USA
Advertisement
Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer's disease. Each patient's planned treatment period is approximately 18 months.